AI assistant
PUMA BIOTECHNOLOGY, INC. — Director's Dealing 2015
Jul 8, 2015
33488_dirs_2015-07-08_27d80930-fabf-4fa1-8033-02afb4f82c06.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK: 0001401667
Period of Report: 2015-07-06
Reporting Person: BRYCE RICHARD PAUL (SR VP, CLINICAL RESEARCH & DEV)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2015-07-06 | COMMON STOCK | M | 3000 | $11.30 | Acquired | 3030 | Direct |
| 2015-07-06 | COMMON STOCK | S | 3000 | $110.028 | Disposed | 30 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2015-07-06 | STOCK OPTION (RIGHT TO BUY) | $11.30 | M | 3000 | Disposed | 2022-06-26 | COMMON STOCK (3000) | Direct |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 4, 2015.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3: The option is fully vested and is exercisable.